Press release from Companies

Published: 2021-12-23 14:25:31

CS MEDICA A/S: CS MEDICA A/S: Update on IPR rights

CS MEDICA A/S ("CS MEDICA" or the "Company") announces that an additional five Intellectual Property Rights (IPR) registrations have been made for CANNASEN, and the Company hereby provides an update on the Company’s IPR and trademark.

CS MEDICA’s product line, CANNASEN® CBD is the world’s first over-the-counter medical technical treatment products with cannabinoids. Intellectual Property Rights (IPR) is a key element for CS MEDICA to ensure economic growth and is continually extended when entering new markets.

CS MEDICA can now confirm that the Company has officially completed an additional five IPR registrations for CANNASEN. These include the United Kingdom, Hong Kong, Australia, New Zealand and Turkey. Previously, the applications were pending and are now officially filed.

The trademark application filed for the world’s first over-the-counter medical technical treatment products with cannabinoids from cannabis is CANNASEN.

The following countries are now secured:

Trademark.................... Country.................... Status.................... Applicationdate.................... Registration date
CANNASEN EU Registered
 2018-10-24
2019-02-21
CANNASEN International Protocol Registered
 2018-11-19
2018-11-19
CANNASEN Norway Registered
 2018-11-19
2019-12-20
CANNASEN Switzerland Registered
 2018-11-19
2019-11-05
CANNASEN Canada Pending
 2020-01-20
2020-11-09
CANNASEN India Registered
 2020-01-20
2020-11-09
CANNASEN Indonesia Registered
 2020-01-20
2021-03-26
CANNASEN Malaysia Registered
 2020-01-20
2021-07-28
CANNASEN Malaysia Registered  2020-01-20
2021-07-28
CANNASEN Malaysia Registered
 2020-01-20
2021-07-28
CANNASEN Japan Registered
 2020-01-20
2021-09-02
CANNASEN Hong Kong Pending
CANNASEN Hong Kong Published
 2021-11-11
CANNASEN China Pending
CANNASEN South Korea Registered
 2020-01-20
2021-08-19
CANNASEN Thailand Pending
 2020-01-20
CANNASEN Thailand Pending
 2020-01-20
CANNASEN Thailand Pending
 2020-01-20
CANNASEN United States Pending
 2020-01-20
CANNASEN Vietnam Registered
 2020-01-20
2021-08-19
CANNASEN United Kingdom Registered
 2018-10-24
2019-02-21
CANNASEN Brazil Pending
CANNASEN Turkey Filed
 2021-11-12
CANNASEN Australia Filed
 2021-11-12
CANNASEN New Zealand Filed
 2021-11-12
CANNASEN The United Arab Emirate Pending


A paradigm shift in the market of autoimmune and stress-related disorders
There is currently a paradigm shift from traditional pharmaceutical treatments of autoimmune and stress-related disorders to treatment based on natural medication like cannabinoids regulating, re-establishing and maintaining the natural balance in the body.

This paradigm shift follows the previous use of cannabis in medication, where cannabis was the second/third most used medication, for more than 100 different diseases until it was banned in 1937. Today Cannabis is reintroduced into medication and legalized in most countries.

The CANNASEN product line introduces a new product category
The majority of the existing cannabinoid products are listed as food supplements, which currently is illegal. Currently, only products certified as cosmetic or medical devices can legally stay on the market, such as the product line from CS MEDICA; CANNASEN® CBD. But the reintroduction of legal cannabis products for treatment does not fit into any existing product category, as the products cover both medicines and natural products.  Consequently, this calls for the introduction of a new category in the market.  Henceforth, the CANNASEN® CBD product line is introduced as a new product category.  As CS MEDICA is the first company to introduce Medical technical treatment based on cannabinoids within the pharmaceutical legislation, it is crucial to secure the IPR’s before entering new markets.

Current IPR and trademark applications
With the above listed trademarks, along with CS MEDICA’s eleven patents, CS MEDICA aims to protect its business against others using their trademark or copying their product. CS MEDICA protects its trademark by the mentioned global trademarks registration in class 03, 05, and 10;

  • CLASS 3 (Cosmetics)
    Soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices.
  • CLASS 5 (Pharmaceuticals)
    Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.

     
  • CLASS 10 (Medical Apparatus)
    Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; orthopedic articles; suture materials.  

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: "CSMED"). For more information about CS MEDICA cs-medica.com.

Läs mer hos Cision
Read more about CS MEDICA A/S

Subscription